Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (A...
| PYXS | Peers | Sector | |
|---|---|---|---|
Market Cap | 60.352 M | 71.607 M | 62.691 M |
Price % of 52 Week High | 15.4% | 41.2% | 61.8% |
Dividend Yield | 0.0% | 0.0% | 0.0% |
Shareholder Yield | -95.4% | -9.1% | -0.7% |
1 Year Price Total Return | -79.5% | -54.5% | -13.2% |
Beta (5 Year) | 1.11 | 1.08 | 0.64 |
| (presentment in millions) | Trailing Twelve Months | Fiscal Quarters | |||
|---|---|---|---|---|---|
| Period Ending | Dec-22 | Dec-23 | Dec-24 | Dec-23 | Dec-24 |
| Income Statement | |||||
| Revenue | 16 | 0.00 | |||
| Operating Income | (123) | (80) | (66) | (17) | (18) |
| Net Profit | (121) | (74) | (77) | (16) | (36) |
| Diluted EPS | -3.65 | -1.85 | -1.32 | -0.35 | -0.58 |
| EBITDA | (123) | (78) | (63) | (17) | (18) |
| Balance Sheet | |||||
| Cash & ST Invest. | 179 | 119 | 127 | 119 | 127 |
| Current Assets | 187 | 125 | 132 | 125 | 132 |
| Total Assets | 211 | 174 | 157 | 174 | 157 |
| Current Liabilities | 32 | 26 | 18 | 26 | 18 |
| Total Liabilities | 51 | 48 | 36 | 48 | 36 |
| Total Equity | 161 | 126 | 121 | 126 | 121 |
| Total Debt | 19 | 21 | 20 | 21 | 20 |
| Cash Flow Statement | |||||
| Cash Flow Operations | (89) | (71) | (58) | (15) | (19) |
| Cash From Investing | (6.40) | (105) | 8.15 | 10 | 27 |
| Cash From Financing | 0.18 | 5.93 | 59 | (0.03) | 0.05 |
| Free Cash Flow | (96) | (77) | (58) | (15) | (19) |